A single-blind, randomized, controlled, phase II study to evaluate immunogenicity and safety of two doses of the MVA [modified vaccinia Ankara]-Nef HIV vaccine in HIV-1 infected patients with CD4 above 250/microL
Latest Information Update: 03 Nov 2021
At a glance
- Drugs MVA-BN-nef (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 20 Feb 2006 New trial record.